<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="261">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02009449</url>
  </required_header>
  <id_info>
    <org_study_id>AM0010-001</org_study_id>
    <nct_id>NCT02009449</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARMO BioSciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARMO BioSciences</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human, open-label, dose escalation study to evaluate the safety and
      tolerability of AM0010 in patients with advanced solid tumors, dosed daily subcutaneously as
      a monotherapy or in combination with chemotherapy or immunotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability as measured by incidence of adverse events</measure>
    <time_frame>up to 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) parameters</measure>
    <time_frame>up to 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>PK parameters including the serum trough concentration (Minimal Drug Concentration (Cmin)), the maximal drug concentration (Cmax), area under the curve of serum concentration over time (Area Under the Curve/ AUC), and half-life (t½).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in tumor burden measured by volumetric Computer Tomography (CT) or Magnetic Resonance Imaging (MRI) according to immune-related response criteria (irRC)</measure>
    <time_frame>up to 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression in bone by bone scintigraphy according to Prostate Cancer Working Group 2 (PCWG2) for patients with metastatic castration resistant prostate cancer (CRPC)</measure>
    <time_frame>approximatley 4 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-AM0010 antibody formation</measure>
    <time_frame>up to 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>24</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Melanoma</condition>
  <condition>Prostate Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Colorectal Carcinoma</condition>
  <condition>Pancreatic Carcinoma</condition>
  <condition>Non-small Cell Lung Carcinoma</condition>
  <condition>Solid Tumors</condition>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Part A: Dose Escalation Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (1 ug/kg) - Daily subcutaneous (SC) injections of AM0010 for up to 22 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Dose Escalation Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (2.5 ug/kg) - Daily subcutaneous injections of AM0010 for up to 22 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Dose Escalation Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (5 ug/kg) - Daily subcutaneous injections of AM0010 for up to 22 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Dose Escalation Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (10 ug/kg) - Daily subcutaneous injections of AM0010 for up to 22 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Dose Escalation Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (20 ug/kg) - Daily subcutaneous injections of AM0010 for up to 22 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Dose Escalation Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (40 ug/kg) - Daily subcutaneous injections of AM0010 for up to 22 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Dose Expansion Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>at least 15 RCC patients will be dosed with AM0010 for up to 22 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Dose Escalation Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (2.5 ug/kg) daily subcutaneous injections with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.
Day 1
Paclitaxel 200/175 mg/m2 IV, or
Docetaxel 75/65 mg/m2 IV And
Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or
Cisplatin 75mg/m2 IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Dose Escalation Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (5 ug/kg) daily subcutaneous injections with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.
Day 1
Paclitaxel 200/175 mg/m2 IV, or
Docetaxel 75/65 mg/m2 IV And
Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or
Cisplatin 75mg/m2 IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Dose Escalation Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (10 ug/kg) daily subcutaneous injections with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.
Day 1
Paclitaxel 200/175 mg/m2 IV, or
Docetaxel 75/65 mg/m2 IV And
Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or
Cisplatin 75mg/m2 IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Dose Expansion Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily SC injection with AM0010 with Platinum / Taxane combination Every 21 days, (21 days = 1 cycle) for 5 cycles.
Day 1
Paclitaxel 200/175 mg/m2 IV, or
Docetaxel 75/65 mg/m2 IV And
Carboplatin AUC 6/5/4 (max. 6x 150mg) IV or
Cisplatin 75mg/m2 IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: Dose Escalation Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (2.5 ug/kg) daily subcutaneous injections with FOLFOX4 every 14 days FOLFOX4; (14 days = 1 cycle) ;
Day 1
Oxaliplatin 85 mg/m2 IV over 2 hours
Leucovorin 200 mg/m2 IV over 2 hours followed by
5-FU 400 mg/m2 IV bolus and
5-FU 600 mg/m2/day IV over 22 hours
Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by
5-FU 400 mg/m2 IV bolus and
5-FU 600 mg/m2/day IV over 22 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: Dose Escalation Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (5 ug/kg) daily subcutaneous injections with FOLFOX4 every 14 days FOLFOX4; (14 days = 1 cycle) ;
Day 1
Oxaliplatin 85 mg/m2 IV over 2 hours
Leucovorin 200 mg/m2 IV over 2 hours followed by
5-FU 400 mg/m2 IV bolus and
5-FU 600 mg/m2/day IV over 22 hours
Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by
5-FU 400 mg/m2 IV bolus and
5-FU 600 mg/m2/day IV over 22 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: Dose Escalation Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (10 ug/kg) daily subcutaneous injections with FOLFOX4 every 14 days FOLFOX4; (14 days = 1 cycle) ;
Day 1
Oxaliplatin 85 mg/m2 IV over 2 hours
Leucovorin 200 mg/m2 IV over 2 hours followed by
5-FU 400 mg/m2 IV bolus and
5-FU 600 mg/m2/day IV over 22 hours
Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by
5-FU 400 mg/m2 IV bolus and
5-FU 600 mg/m2/day IV over 22 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: Dose Expansion Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily SC injection with AM0010 with FOLFOX4 Every 14 days FOLFOX4; (14 days = 1 cycle) ;
Day 1
Oxaliplatin 85 mg/m2 IV over 2 hours
Leucovorin 200 mg/m2 IV over 2 hours followed by
5-FU 400 mg/m2 IV bolus and
5-FU 600 mg/m2/day IV over 22 hours
Leucovorin 200 mg/m2 IV over 2 hours on Day 2 followed by
5-FU 400 mg/m2 IV bolus and
5-FU 600 mg/m2/day IV over 22 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D: Dose Escalation Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (5 ug/kg) daily subcutaneous injections with Gemcitabine and nab-paclitaxel on Days 1, 8, 15 of each cycle (28 days = 1 cycle).
Nab-paclitaxel 125 mg/m2 IV over 30 minutes followed by
• Gemcitabine 1000 mg/m2 IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part E: Dose Escalation Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (10 ug/kg) daily subcutaneous injections with capecitabine BID daily for 14 days of each cycle (21 days= 1 cycle).
• Capecitabine 1000 mg/m2 po BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part F: Dose Escalation Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (10 ug/kg) daily subcutaneous injections with paclitaxel on Days 1, 8, 15 of each cycle (28 days= 1 cycle)
• Paclitaxel 80 mg/ m2 IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part G: Dose Escalation Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (10 ug/kg) daily subcutaneous injections with pazopanib orally given daily for 14 days of each cycle (21 days= 1 cycle)
• Pazopanib 800 mg po QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part H: Dose Escalation Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (10 ug/kg) daily subcutaneous injections with pembrolizumab on Day 1 of each cycle (21 days= 1 cycle).
• Pembrolizumab 2 mg/kg IV over 30 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I: Dose Escalation Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (20 ug/kg) daily subcutaneous injections with nivolumab on Day 1 of each cycle (14 days= 1 cycle).
• Nivolumab 3 mg/kg IV over 60 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part H: Dose Escalation Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (20 ug/kg) daily subcutaneous injections with pembrolizumab on Day 1 of each cycle (21 days= 1 cycle).
• Pembrolizumab 2 mg/kg IV over 30 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part H: Dose Escalation Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (40 ug/kg) daily subcutaneous injections with pembrolizumab on Day 1 of each cycle (21 days= 1 cycle).
• Pembrolizumab 2 mg/kg IV over 30 min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part J: Dose Escalation Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM0010 (10 ug/kg) daily subcutaneous injections with gemcitabine and carbolplatin on Days 1,8 of each cycle (21 days=1 cycle) until disease progression gemcitabine 1000mg/m2 IV over 30 minutes followed by carboplatin AUC2 over 60 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AM0010</intervention_name>
    <description>Daily subcutaneous injections of AM0010 up to 12 months</description>
    <arm_group_label>Part A: Dose Escalation Cohort 1</arm_group_label>
    <arm_group_label>Part A: Dose Escalation Cohort 2</arm_group_label>
    <arm_group_label>Part A: Dose Escalation Cohort 3</arm_group_label>
    <arm_group_label>Part A: Dose Escalation Cohort 4</arm_group_label>
    <arm_group_label>Part A: Dose Escalation Cohort 5</arm_group_label>
    <arm_group_label>Part A: Dose Escalation Cohort 6</arm_group_label>
    <arm_group_label>Part A: Dose Expansion Cohort 1</arm_group_label>
    <arm_group_label>Part B: Dose Escalation Cohort 1</arm_group_label>
    <arm_group_label>Part B: Dose Escalation Cohort 2</arm_group_label>
    <arm_group_label>Part B: Dose Escalation Cohort 3</arm_group_label>
    <arm_group_label>Part B: Dose Expansion Cohort</arm_group_label>
    <arm_group_label>Part C: Dose Escalation Cohort 1</arm_group_label>
    <arm_group_label>Part C: Dose Escalation Cohort 2</arm_group_label>
    <arm_group_label>Part C: Dose Escalation Cohort 3</arm_group_label>
    <arm_group_label>Part C: Dose Expansion Cohort 1</arm_group_label>
    <arm_group_label>Part D: Dose Escalation Cohort 1</arm_group_label>
    <arm_group_label>Part E: Dose Escalation Cohort 1</arm_group_label>
    <arm_group_label>Part F: Dose Escalation Cohort 1</arm_group_label>
    <arm_group_label>Part G: Dose Escalation Cohort 1</arm_group_label>
    <arm_group_label>Part H: Dose Escalation Cohort 1</arm_group_label>
    <other_name>PEGylated recombinant human Interleukin-10</other_name>
    <other_name>PEG-rHuIL-10</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel or Docetaxel and Carboplatin or Cisplatin</intervention_name>
    <description>Day 1 of every 21 day cycle</description>
    <arm_group_label>Part B: Dose Escalation Cohort 1</arm_group_label>
    <arm_group_label>Part B: Dose Escalation Cohort 2</arm_group_label>
    <arm_group_label>Part B: Dose Escalation Cohort 3</arm_group_label>
    <arm_group_label>Part B: Dose Expansion Cohort</arm_group_label>
    <other_name>Taxol or taxotere and paraplatin or platinol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)</intervention_name>
    <description>Intravenous administration on Day 1 and 2 of every 14 day cycle</description>
    <arm_group_label>Part C: Dose Escalation Cohort 1</arm_group_label>
    <arm_group_label>Part C: Dose Escalation Cohort 2</arm_group_label>
    <arm_group_label>Part C: Dose Escalation Cohort 3</arm_group_label>
    <arm_group_label>Part C: Dose Expansion Cohort 1</arm_group_label>
    <other_name>Eloxatin®/Leucovorin/5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine/nab-paclitaxel</intervention_name>
    <description>Intravenous administration of the gemcitabine/nab-paclitaxel regimen on Day 1, 8 and 15 of each 28 day treatment cycle.</description>
    <arm_group_label>Part D: Dose Escalation Cohort 1</arm_group_label>
    <other_name>Gemzar/Abraxane ABI-007</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine will be administered orally twice daily for 14 days out of every 21 days.</description>
    <arm_group_label>Part E: Dose Escalation Cohort 1</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <description>Pazopanib will be administered orally daily continuously</description>
    <arm_group_label>Part G: Dose Escalation Cohort 1</arm_group_label>
    <other_name>GW786034</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab will be administered intravenously on Day 1 of every 21 day cycle.</description>
    <arm_group_label>Part H: Dose Escalation Cohort 1</arm_group_label>
    <arm_group_label>Part H: Dose Escalation Cohort 2</arm_group_label>
    <arm_group_label>Part H: Dose Escalation Cohort 3</arm_group_label>
    <other_name>Keytruda, MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel will be administered intravenously on Days 1, 8, 15 of each cycle (28 days= 1 cycle)
• Paclitaxel 80 mg/ m2 IV</description>
    <arm_group_label>Part F: Dose Escalation Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nivolumab</intervention_name>
    <description>Nivolumab on Day 1 of each cycle (14 days = 1 cycle)</description>
    <arm_group_label>Part I: Dose Escalation Cohort 1</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine/carboplatin</intervention_name>
    <description>gemcitabine and carboplatin on Days 1, 8 of each cycle (21 days = 1 cycle)</description>
    <arm_group_label>Part J: Dose Escalation Cohort 1</arm_group_label>
    <other_name>gemzar/paraplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Part A Escalation Cohorts:

        o Histologically or cytologically confirmed advanced malignant solid tumor, limited to
        melanoma, castrate resistant prostate cancer (CRPC), ovarian cancer (OVCA), renal cell
        carcinoma, colorectal carcinoma (CRC), pancreatic carcinoma or non-small cell lung
        carcinoma (NSCLC) that is refractory to, intolerant of, for which no standard of therapy
        is available or where the patient refuses existing therapies

        Part A Expansion Cohorts, Part B and C Escalation and Expansion Cohorts:

          -  Tumors with all histological diagnosis or tissue origin may be enrolled

          -  Patients must have failed prior standard curative chemotherapy for their disease,
             refuse existing therapies OR the proposed chemotherapy regimen to which AM0010 is
             added represents an acceptable standard treatment for their disease.

               -  Measurable or evaluable disease according to irRC or bone metastatic disease
                  evaluable by Prostate Cancer Working Group 2 criteria (PCWG2) for
                  castration-resistant prostate cancer (CRPC)

               -  At least 18 years of age

               -  Performance Status of 0 or 1

               -  Adequate organ function

        Exclusion Criteria:

          -  Hematologic malignancies

          -  Pregnant or lactating

          -  Present or history of neurological disorders such as Multiple Sclerosis and Guillain
             Barre or inflammatory central nervous system/peripheral nervous system (CNS/PNS)
             disorders

          -  Myocardial infarction within the last 6 months

          -  Unstable angina, or unstable cardiac arrhythmia requiring medication

          -  Surgery within the last 28 days

          -  Systemic fungal, bacterial, viral, or other infection

          -  History of bleeding diathesis within the last 6 months

          -  Positive for human immunodeficiency virus (HIV), hepatitis C, or hepatitis B
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Oft, MD</last_name>
    <role>Study Director</role>
    <affiliation>ARMO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Medical Hematology &amp; Oncology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liz Seja</last_name>
      <phone>310-794-6892</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamran AbriLavasani</last_name>
      <email>Kamran.AbriLavasani@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at HealthONE</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Hannan</last_name>
      <email>lori.hannan@healthonecares.com</email>
    </contact>
    <investigator>
      <last_name>Gerald Falchook</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists &amp; Research Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Akins</last_name>
      <email>aakins@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caryn Kata</last_name>
      <phone>617-582-7603</phone>
    </contact>
    <investigator>
      <last_name>Patrick Ott, MD, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Autio, MD</last_name>
      <phone>646-888-3359</phone>
    </contact>
    <investigator>
      <last_name>Karen Autio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center at Oklahoma University TSET Phase 1 Program</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Benjamin</last_name>
      <phone>405-271-8778</phone>
      <email>kimberly-Benjamin@ouhsc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brianna Hawkins</last_name>
      <phone>877-691-7274</phone>
    </contact>
    <investigator>
      <last_name>Jeffrey Infante, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aung Naing</last_name>
      <phone>713-563-1930</phone>
    </contact>
    <investigator>
      <last_name>Naing Aung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Jimenez, RN, MSN</last_name>
      <phone>210-593-5265</phone>
      <email>isabel.jimenez@start.stoh.com</email>
    </contact>
    <investigator>
      <last_name>Kyrakos Papadopoulos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 11, 2016</lastchanged_date>
  <firstreceived_date>December 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1/Phase 1b</keyword>
  <keyword>Oncology</keyword>
  <keyword>Cancer</keyword>
  <keyword>Solid Tumors</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
